drugset / Trial / NCT01478581
Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The primary objective of this study is to determine the efficacy of PCI-32765, both as a single agent and in combination with dexamethasone, in subjects with relapsed or relapsed and refractory Multiple Myeloma (MM)
Timeline
- Start
- 2012-03
- Primary completion
- 2018-08
- Completion
- 2018-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dexamethasone | Small molecule | 40 mg | Oral |
| Subject | Ibrutinib | Small molecule | 420 mg | — |
| Subject | Ibrutinib | Small molecule | 560 mg | — |
| Subject | Ibrutinib | Small molecule | 840 mg | — |